Investigational drug · Phase 3
RC118
Also called: RC118-ADC
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "RC118"
First trial start
2022
Mar 3, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RC118", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RC118" as an intervention, largest first.
- RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ AdenocarcinomaPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07935369 · 680 participants (planned) · Start Nov 2026 · Primary completion Apr 30, 2030
Drug: RC118(Dose 1) plus RC148(Dose 1); RC118(Dose 1) plus RC148(Dose 2) and 4 more · For: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China; Shanghai, China
- A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsRecruiting
RemeGen Co., Ltd.Industry
NCT05205850 · 135 participants (planned) · Start Mar 3, 2022 · Primary completion Sep 30, 2025
Drug: RC118-ADC · For: Advanced Solid Tumor
Sites: Shanghai, China; Hangzhou, China
- A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid TumorsStatus unknown
RemeGen Co., Ltd.Industry
NCT06038396 · 48 participants (planned) · Start Aug 3, 2023 · Primary completion Feb 28, 2026
Drug: RC118; Toripalimab and 1 more · For: Advanced Solid Tumor
Sites: Fuzhou, China; Xiamen, China; Wuwei, China · 18 sites in all
- MPN-RC 118 AVID200 in MyelofibrosisCompleted
John MascarenhasAcademic, hospital or other
NCT03895112 · 21 participants · Start Feb 15, 2019 · Primary completion May 16, 2022
Drug: AVID200 · For: Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis and 2 more
Sites: New York, New York
RemeGen Co., Ltd.Industry
NCT04914117 · 7 participants · Start Nov 29, 2021 · Primary completion Nov 15, 2022
Drug: RC118 for injection · For: Unresectable Solid Tumor; Metastatic Solid Tumor; Locally Advanced Solid Tumor
Sites: Macquarie Park, Australia; Bedford Park, Australia; Frankston, Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A multiscale quantitative systems pharmacology platform for early screening of MMAE-based antibody-drug conjugates.
Li Q, Wang L, Bi S, et al. · Eur J Pharm Sci 2026
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.